Chronic Myeloid Leukemia News and Research

RSS

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.

Make Sense campaign aims to promote better quality of life for head and neck cancer survivors

On the advent of the 2017 Head and Neck Cancer Awareness Week, the European Cancer Patient Coalition invited patients and policy makers to gather at the European Parliament to promote better quality of life for cancer patients and survivors as part of the Make Sense Campaign.

19 Sep 2017

Cancer drug may inhibit growth of cysts in patients with inherited form of kidney disease

A cancer drug called bosutinib may inhibit the growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

24 Aug 2017

Study provides new insight into development of immune cells

In contrast to what has been previously believed, development of blood stem cells to mast cells, a type of specialized immune cell, does not depend on a growth factor called stem cell factor.

10 Aug 2017

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects.

12 Jul 2017

Researchers identify new drug target for two common types of myeloid leukemia

University of Georgia researchers, with colleagues from the University of Tokyo, have identified a new drug target for the two most common types of myeloid leukemia, including a way to turn back the most aggressive form of the disease.

17 May 2017

Formaldehyde exposure not linked to leukemia, research shows

Some scientific reports have a profound impact on government policy. Sometimes, however, there are significant shortcomings in the research - yet the policy impact continues.

2 May 2017

Scientists launch new virtual platform to aid global search for treatment of leukemia

Finding a cure for a rare type of blood cancer could be accelerated by a new virtual platform that allows researchers easy access to data from patient samples generated by laboratories around the world.

29 Apr 2017

Study identifies potential Achilles heel of kinase-driven cancers

Scientists identify two signaling proteins in cancer cells that make them resistant to chemotherapy, and show that blocking the proteins along with chemotherapy eliminate human leukemia in mouse models.

22 Mar 2017

GUMC launches phase II clinical study to examine safety of cancer drug for Parkinson's disease

Georgetown University Medical Center today announces the launch of a phase II clinical trial to study the safety of the cancer drug nilotinib and its effects on clinical outcomes and biomarkers in people with Parkinson's disease.

27 Feb 2017

Salk professor receives inaugural Sjöberg Prize for groundbreaking cancer research

Salk Professor Tony Hunter, who holds an American Cancer Society Professorship, has been awarded $500,000 as part of the $1 million Royal Swedish Academy of Sciences' inaugural Sjöberg Prize for Cancer Research for "groundbreaking studies of cellular processes that have led to the development of new and effective cancer drugs."

14 Feb 2017

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North Carolina Lineberger Comprehensive Cancer Center-led study.

4 Oct 2016

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease.

29 Sep 2016

Researchers develop new test for early detection of patients' resistance to leukemia treatment

Australian researchers have made a world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukemia.

28 Jul 2016

Potential therapeutic approaches to combat chronic myeloid leukemia

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer.

21 Jun 2016

RNA editing enzyme ADAR1 may play role in regeneration of leukemia stem cells

Cancer stem cells are like zombies — even after a tumor is destroyed, they can keep coming back. These cells have an unlimited capacity to regenerate themselves, making more cancer stem cells and more tumors.

10 Jun 2016

High out-of-pocket costs linked to lower use of specialty drugs

"Specialty drugs" have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival.

29 Mar 2016

Gleevec could be novel therapeutic agent for type 2 diabetes

The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for it, curing type 2 diabetes.

28 Mar 2016

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued.

8 Feb 2016

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

An international team of scientists, headed by researchers at UC San Diego School of Medicine and UC San Diego Moores Cancer Center, report that decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs).

1 Dec 2015

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell.

28 Aug 2015